Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03108352
Other study ID # KH902-BRVO-CRP-1.0
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date April 13, 2016
Est. completion date October 16, 2020

Study information

Verified date July 2022
Source Chengdu Kanghong Biotech Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to verify the efficacy and safety of intravitreal injection of conbercept in patients with macular edema (ME) caused by branch retinal vein occlusion (BRVO).


Recruitment information / eligibility

Status Completed
Enrollment 255
Est. completion date October 16, 2020
Est. primary completion date April 13, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients have signed informed consent form and agreed to be followed up as per the trial protocol; - Aged = 18 years, male or female; - Study eyes must meet all of following requirements: - Suffering from macular edema secondary to BRVO that involves the fovea and BRVO has been first diagnosed within previous 12 months; - Best corrected visual acuity (BCVA) =24 and =73 letters (Snellen equivalent is 20/320 - 20/40); - Central retinal thickness (CRT) on OCT is =300 µm; - Without opacities in the refractive media and pupillary miosis that affects fundus examination. Note: The eye of interest is determined by the researcher from a medical point of view if both eyes of the patient meet the inclusion criteria. In principle, the eye with poor eyesight or thicker central retina should be selected as the eye of interest. Exclusion Criteria: Any subject who has any of the following ocular condition: 1. Eye of interest - Has active retina and/or iris neovascularization; - Has macular epiretinal membranes or vitreous tractions which are considered to influence the central visual acuity by the researcher; - Has other diseases which are considered to influence the macular functional recovery by the researcher, e.g., foveal atrophy, subfoveal hemorrhage, macular hard exudates or dense submacular hard exudates; - Has a history of any type of retinal detachment; - Has non-RVO ocular diseases which are considered to possibly cause macular edema, declined visual acuity or retinal neovascularization during the study period by the researcher, e.g., wet AMD, diabetic retinopathy, uveitis/other intraocular inflammatory diseases, neovascular glaucoma and cystoid macular edema; - Is considered to require cataract surgery in the next 12 months by the researcher; - Has received intravitreal injection of corticosteroids within three months before screening, subconjunctival injection of corticosteroids within six months, or local treatment with ocular corticosteroids within one month; - Has received the following ophthalmic operations: scleral buckling, verteporfin-photodynamic therapy (PDT), vitrectomy, radial optic neurotomy/optic nerve sheathotomy, glaucoma filtration, parafoveal laser photocoagulation, pan-retinal photocoagulation, and macular translocation; - Has received YAG laser treatment or any other ophthalmic treatments (including cataract surgery, macular grid laser photocoagulation, local retinal photocoagulation, and keratoplasty) within three months before screening; - Has a BCVA increment by more than 10 alphabets during the screening period (BCVA tested within 24 hours before medication at Day 0 versus BCVA at the time of screening); - Has aphakic eye (excluding pseudophakic) or or posterior lens capsule (except YAG laser posterior capsulotomy after intraocular lens implantation); 2. Either eye: - Has active periocular or ocular inflammation (e.g., blepharitis, infective conjunctivitis, keratitis, scleritis, uveitis, and endophthalmitis); - Has previous or existing uncontrollable glaucoma (defined as IOP remaining at = 30 mmHg after anti-glaucoma treatment), or has a cup-to-disc ratio of the eye of interest of above 0.8 due to severe glaucoma; - Has received intravitreal injection of any anti-VEGF agents (e.g.,ranibizumab, bevacizumab, and conbercept) within three months before screening; Patient with any of the following systemic diseases: - Has a history of anaphylaxis and allergy to fluorescein sodium, and of allergy to protein products for diagnosis or treatment, and is allergic to no less than two drugs and/or non-drug factors, or suffers from allergic diseases now; - Has a history of stroke, has a history of myocardial and/or cerebral infarction(s) and of transient cerebral ischemia within 6 months before screening, and has active and disseminated intravascular coagulation and distinct bleeding tendency; - Has confirmed systemic immune disease (e.g., ankylosing spondylitis, systemic lupus erythematosus, and Behcet's disease, rheumatoid arthritis, and scleroderma); - Has any uncontrollable clinical problem (e.g., AIDS, active hepatitis, severe mental, neurological, cardiovascular and respiratory diseases, and malignancies); - Hyperpietics with poor blood pressure control (defined as SBP remaining at = 160 mmHg or DBP remaining = 100 mmHg after antihypertensives therapy); - Has a surgical history within one month before screening, and/or has unhealed wounds, ulcers and fractures at present; - Has systemically used corticosteroids (orally, intramuscularly, intravenously) within 6 months before screening; - Has received systemic treatment with anti-VEGF agent(s) (e.g., bevacizumab) within 6 months before screening; Patients with any of the following abnormal laboratory tests - Those who have hepatic, renal and immunologic dysfunction (this trial specifies that ALT and AST are twice as high as the ULN of this central laboratory, and that Crea and BUN are 1.5-fold as high as the ULN of this central laboratory); - Those who have coagulation abnormalities (PT is 3 seconds greater than or equal to the ULN, and APTT is 10 seconds greater than or equal to the ULN); Patients of childbearing age with any of the following condition - Those who do not take effective contraceptive measures at childbearing age; Note: The following conditions are not included in the exclusion range. 1. Amenorrhea for 12 months under the natural condition, or amenorrhea for 6 months under the natural condition and the serum FSH level of < 40 mIU/ml; 2. Six weeks after bilateral ovariectomy with/without hysterectomy; 3. Use of the following one or more acceptable contraceptions: - Sterilization (for males, with bilateral vasoligation and vasectomy) - Hormonal contraception (implantable, patchable, oral) - Intrauterine device and dural barrier method 4. Ability to take reliable contraceptive measures over the study period and hold on to 30 days after study drug withdrawal (unacceptable contraceptive methods include: periodic continence - according to the calendar and ovulatory phase, body thermometry, post-ovulatory method, and coitus interruptus); - Pregnant women and breastfeeding mothers (in this trial pregnancy is defined as positive U-HCG); Others - Patient has participated in any drug (not including vitamins and minerals) clinical trial three months before screening (if the study drug has a long half-life, i.e., its five half-lives exceed three months, then it is deemed as five half-lives); Any condition in which the researcher deems necessary to be excluded in the study.

Study Design


Intervention

Drug:
Conbercept ophthalmic injection
Conbercept ophthalmic injection at a dose of 0.5 mg every month(day0-month 5); If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 6 ~ 11)
Other:
sham/Conbercept ophthalmic injection
Sham injection every month (Day 0 - Month 5); 0.5 mg Conbercept ophthalmic injection in month 6; If sbujects meets the criteria for repeated administration, the subject receives 0.5 mg Conbercept injection into the study eye (Month 7 ~ 11)

Locations

Country Name City State
China Beijing Friendship Hospital, Capital Medical University Beijing
China Peking Union Medical College Hospital Beijing
China Peking University First Hospital Beijing
China Peking University People's Hospital Beijing
China Peking University Third Hospital Beijing
China The General Hospital of the People's Liberation Army Beijing Beijing
China The Second Hospital of Jilin University Changchun
China The Second Xiangya Hospital of Central South University Changsha
China West China Hospital Sichuan University Chengdu
China Army Medical Center Chongqing
China The Second Hospital of Dalian Medical University Dalian
China Zhongshan Ophthalmic Center, Sun Yat-Sen University Guangzhou
China The Second Affiliated Hospital Zhejiang University School of Medicine Hangzhou
China The 2nd Affiliated Hospital of Harbin Medical University Harbin
China The Jiangxi Provincial People's Hospital Nanchang
China Jiangsu Province Hospital Nanjing
China Nanjing First Hospital Nanjing
China The First Affiliated Hospital of Guangxi Medical University Nanning
China Beijing Tongren Hospital, Capital Medical University Peking
China Eye & Ent Hospital of Fudan University Shanghai
China Shanghai General Hospital Shanghai
China Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai
China Zhongshan Hospital Shanghai
China The First Hospital of China Medical University Shenyang
China Tianjin Medical University Eye Hospital School of Optometry & Eye Institute Tianjin
China Tianjin Eye Hospital Tianjing
China The First Affiliated Hospital of Xinjiang Medical University Urumqi
China Eye Hospital,WMU Zhejiang Eye Hospital Wenzhou
China Wuhan General Hospital of Guangzhou Military Command Wuhan
China Wuxi No.2 People's Hospital Wuxi
China The First Affiliated Hospital of Xi'An Xi'an

Sponsors (1)

Lead Sponsor Collaborator
Chengdu Kanghong Biotech Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Immunogenic positive response in the treatment group Number of participants with Treatment-Ralated positive response to anti-drug antibody(ADA)or neutralizing antibody(Nab) in the treatment group at baseline,6 and 12months. baseline,month 6, month 12
Other Immunogenic positive response in the control group Number of participants with Treatment-Ralated positive response to anti-drug antibody(ADA)or neutralizing antibody(Nab) in thecontrol group at baseline,6 and 12months. baseline,month 6, month 12
Other safety analysis of immunogenic positive response To analyze the safely of subjects with positive response to ADA or Nab at 12 months after treatment and number of participants with positive respone who develop anticipants immuogenic adverse events. month 12
Other safety analysis of immunogenic negative response To analyze the safely of subjects with negative response to ADA or Nab at 12 months after treatment and number of participants with negative response who develop anticipants immuogenic adverse events. month 12
Other Best Corrected Visual Acuity (BCVA) To analyze the BCVA for subjects with positive response to ADA or Nab at 12 months after treatment. month 12
Primary Best Corrected Visual Acuity Compare mean changes in Best Corrected Visual Acuity (BCVA) from baseline between the Conbercept ophthalmic injection treatment group (treatment group) and the control group at month 6. month 6
Secondary Best Corrected Visual Acuity (BCVA) 1>o evaluate mean changes in BCVA from baseline of the treatment group and the control group at month 3 and 12. month 3 and month 12
Secondary Central Retinal Thickness To evaluate mean changes in Central Retinal Thickness (CRT) from baseline of the treatment group and the control group at month 3, 6 and 12. month 3, month 6 and month 12
Secondary resue treament To evaluate the number of subjects who received laser rescue treatment of the treatment group and the control group at month 6 and 12. month 6 and month 12
Secondary Number of participants with treatment-related the systemic and ocular safely as assessed To evaluate the systemic and ocular safety of the treatment group and the control group. up to 12.5 months
Secondary distribution of BCVA changes To evaluate the distribution of BCVA changes from baseline of the treatment group and the control group at month 3, 6 and 12. month 3, month 6 and month 12
Secondary mean changes in BCVA To evaluate mean changes in BCVA from baseline of the treatment group and the control group at every visit. month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12
Secondary Change in image To evaluate the average changes in imaging findings (e.g., CRT and total macular volume) relative to the baseline for treatment group and control group at each follow-up visit. month 0,month 1,month 2,month 3,month 4,month 5,month 6,month 7,month 8,month 9,month 10,month 11 and month 12
See also
  Status Clinical Trial Phase
Completed NCT04292912 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2798745 in Participants With Diabetic Macular Edema Phase 1
Recruiting NCT05976139 - Micropulsed Laser in Patients With Macular Oedema in Retinal Dystrophies N/A
Completed NCT03660371 - ILM Peeling in PDR Patients Undergoing PPV for VH N/A
Completed NCT03660345 - PPV With Internal Limiting Membrane Peeling for Treatment-Naïve DME Phase 3
Completed NCT01660802 - Safety and Efficacy Study of Dexamethasone in the Treatment of Patients With Macular Edema Following Retinal Vein Occlusion (RVO) Phase 3
Completed NCT01908816 - An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Phase 3
Completed NCT04592419 - A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO) Phase 3
Completed NCT02867735 - A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema Phase 1
Completed NCT02623673 - Simultaneous Therapy With Intravitreal Dexamethasone Implant and Bevacizumab for the Treatment of Macular Edema N/A
Terminated NCT01946399 - Ozurdex Implant for Macular Edema After Treatment Failure With Anti-VEGF N/A
Completed NCT01428388 - Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion N/A
Completed NCT01231633 - Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO) N/A
Recruiting NCT01023113 - To Compare Visual Field Impairment in Conventional Double Frequency Nd: YAG Panretinal Photocoagulation With PASCAL Panretinal Photocoagulation N/A
Completed NCT00970957 - Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion Phase 3
Terminated NCT00969293 - Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion Phase 1
Terminated NCT00918554 - Efficacy Study of Methotrexate to Treat Sarcoid-associated Uveitis Phase 4
Completed NCT00476593 - Retinal OCT and (mfERG) Related to Age, Sex, and the Use of Anti-inflammatory Medications N/A
Completed NCT00668239 - Diffuse Diabetic Maculopathy With Intravitreal Triamcinolone or Laser N/A
Completed NCT00411970 - 20- Versus 23- Gauge System for Pars Plana Vitrectomy Phase 4
Terminated NCT01939691 - Macular Edema Nepafenac vs. Difluprednate Uveitis Trial Phase 4